Avantor, Inc. (AVTR)

NYSE • Healthcare

$17.29

+$0.14 (+0.8%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$17.1

Previous Close$17.29

Day Range$16.9 - $17.32

Avg. Volume (3M)9.3M

Market Cap$11.6B

52 Week Range

$7.27$17.45

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$1.6B100%

Gross Profitminus cost of goods$537M32%

Operating Incomeminus R&D and overhead$121.8M7%

Net Incomeminus taxes and the rest$38.1M2%

In plain terms: out of every $100 in revenue, Avantor, Inc. keeps $2 as net profit.

Fundamentals & Financials

Revenue (TTM)

$6.5B

Net Income (TTM)

-$578M

EPS (TTM)

-$0.84

ROA (TTM)

-4.98%

Current Ratio

1.78

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-4.0%Q3 2025$0.24

-2.1%Q4 2025$0.22

+4.8%Q1 2026$0.22

+8.3%Q2 2026$0.17

+9.7%Q3 2026$0.21

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +9.7%

Avantor’s adjusted EPS of $0.21 topped the $0.19 estimate by 9.7%, and revenue of about $1.7 billion beat the $1.6 billion consensus by 5.1% in the second fiscal quarter of 2026, reported July 29, based on preliminary results. Revenue rose about 1% from $1.68 billion a year ago, with gross profit of about $537 million leaving gross margin near 32% and operating margin around 7%. Adjusted EPS fell about 13% from $0.24 a year ago, while net income came to about $38.1 million, down about 41% from roughly $64.7 million a year ago; operating cash flow was about $17.4 million. For the next period, consensus calls for EPS of $0.20 on revenue of $1.64 billion.

Next report — what to expect

Avantor, Inc. (AVTR) reports next on October 28, 2026. Wall Street expects EPS of $0.208 on revenue of $1.64 billion. For trailing context, revenue rose +0.5% year over year last quarter. The company has beaten EPS in 5 of its 8 most recent quarters, making any margin and demand updates key watch items.

View full earnings history

About Avantor, Inc.

Avantor, Inc. trades on the NYSE as AVTR and supplies the healthcare research and production market with laboratory materials, equipment, and support services across the broader medical tools and supplies business. Across this medical tools and supplies business, it generated $6.6 billion of revenue in FY2025.

Name

Avantor, Inc.

CEO

Emmanuel Ligner

Website

www.avantorsciences.com

Industry

Healthcare

Year Founded

1904

Employees

13,500

Today's Snapshot

AI-generated

AVTR closed 0.8% above yesterday's close, outperforming a weaker sector. Shares changed hands at about two-thirds of its usual level. Avantor reported growth returning in its distribution business under CEO Emmanuel Ligner’s turnaround plan.

Trading Volume

Below 10d avg (10.3M)

6.7M

vs S&P 500 Today

Outperforming Market

+1.34%

Updated: October 23, 2026 at 20:10 UTC

AVTR Headlines

Healthcare stocks fall after weak US jobs data

March 6, 2026

3 min read

View All News

Technical Indicators

6 Buy0 Neutral2 Sell

AVTR shows a strong bullish bias on multiple fronts, with a high ADX indicating a powerful trend and short- to long-term averages well below the current price, signaling broad-based strength. Momentum is mixed — MACD and CCI are bullish while RSI and stochastics are overbought — and price is trading near the upper Bollinger band with contained volatility by ATR. Volume measures indicate accumulation, reinforcing the trend despite overbought readings, and the classic pivot sits just below the market. Technical takeaway: Strong Buy.

All signals